# The impact of B‐cell reconstitution on mRNA vaccine responses in allogeneic stem cell transplant recipients

**Authors:** Fredrika Hellgren, Rodrigo Arcoverde Cerveira, Gustaf Lindgren, Puran Chen, Klara Lenart, Sebastian Ols, Alberto Cagigi, Davide Valentini, Mireia Rocavert Barranco, Evangelin Shaloom Vitus, Martin Corcoran, Yong‐Dae Gwon, Mattias NE Forsell, Magnus Evander, Peter Bergman, Marcus Buggert, Hans‐Gustaf Ljunggren, Soo Aleman, Gunilla B Karlsson Hedestam, Andreas Björklund, Anna Nordlander, Per Ljungman, Stephan Mielke, Karin Loré

PMC · DOI: 10.1002/cti2.70077 · 2026-02-11

## TL;DR

This study examines how B-cell recovery after stem cell transplants affects responses to mRNA vaccines, finding that timing and immature B-cell levels influence vaccine effectiveness.

## Contribution

The study provides new insights into B-cell reconstitution and vaccine responses in alloHCT recipients using BCR repertoire sequencing and immunophenotyping.

## Key findings

- AlloHCT patients vaccinated within 12 months post-transplant had lower antibody levels and memory B-cell frequencies than healthy controls.
- Vaccine-specific B-cell clonotypes in responders showed similar expansion and SHM as in controls, despite reduced overall SHM in alloHCT patients.
- Pre-vaccination immature B-cell levels were negatively correlated with vaccine response and could predict antibody titers.

## Abstract

Vaccine responses in haematopoietic stem cell transplant (alloHCT) recipients vary, with different degrees of B‐cell reconstitution likely playing a key role. However, mechanistic understanding of the B‐cell receptor (BCR) repertoire and its functional impact post‐alloHCT remain limited.

Within the scope of a mRNA SARS‐CoV‐2 vaccine phase IV clinical trial in alloHCT recipients (n = 77), we have measured antibody titers and avidity, and performed B‐cell immunophenotyping and B‐cell receptor repertoire sequencing in sub‐populations.

AlloHCT patients receiving prime‐boost mRNA vaccination within 12 months post‐transplant exhibited lower vaccine‐specific antibody levels and memory B‐cell frequencies than vaccinated healthy controls. Responses were comparable to healthy controls in patients vaccinated later than 12 months post transplant. BCR repertoire sequencing showed reduced somatic hypermutation (SHM) levels in bulk IgG+ B cells from alloHCT patients. Although some alloHCT patients showed exceptional expansion of a few IgG clones of unknown specificity, their overall B‐cell repertoires remained polyclonal. Vaccine‐specific B‐cell clonotypes detected in patients responding to vaccination showed similar proportional expansion and SHM as in controls. The level of immature CD24hiCD38hi transitional B cells pre‐vaccination was negatively correlated to the vaccine response, and can be used as a predictor of antibody titres.

Our data indicate that mRNA vaccination can stimulate expansion of vaccine‐specific B cells to affinity mature in many alloHCT recipients, though restricted by the presence of immature B‐cell populations.

We characterised B‐cell responses to vaccination in allogeneic haematopoietic stem cell transplant (alloHCT) recipients. While mRNA prime‐boost vaccination stimulated expansion of vaccine‐specific B cells to affinity mature in a majority of alloHCT recipients, responses were variable and seemingly restricted by the presence of immature B‐cell populations.

## Linked entities

- **Diseases:** SARS-CoV-2 (MONDO:0100096)

## Full-text entities

- **Species:** Homo sapiens (human, species) [taxon 9606], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12892404/full.md

---
Source: https://tomesphere.com/paper/PMC12892404